CR/iStock via Getty Images Regeneron Pharmaceuticals (NASDAQ:REGN) is planning to conduct a trial to test a combination therapy involving Novo Nordisk's (NVO) obesity drug Wegovy this year in an attempt to improve its effects, CEO George Yancopoulos said. He noted that REGN has clinically validated antibodies that can address the loss of muscle mass, a common issue linked to GLP-1 drugs such as Wegovy, which are indicated in the U.S.

首席执行官乔治·扬科波洛斯（GeorgeYancopoulos）表示，CR/iStock通过Getty Images Regeneron Pharmaceuticals（NASDAQ:REGN）计划今年进行一项试验，测试一种涉及诺和诺德（Novo Nordisk）肥胖药物Wegovy的联合疗法，以期改善其效果。他指出，REGN具有经过临床验证的抗体，可以解决肌肉质量的损失，这是一个与GLP-1药物（如Wegovy）相关的常见问题，美国已经指出。

for obesity and diabetes. 'So pretty exciting, incredible data and opportunity, and we'll be initiating our trial this year to test these muscle preservation agents in combination with semaglutide,' Yancopoulos said during the company's presentation at the J.P. Morgan Healthcare Conference on Tuesday.

肥胖和糖尿病。”Yancopoulos在周二摩根大通（J.P.Morgan）医疗保健会议上的演讲中说，这是一个非常令人兴奋、令人难以置信的数据和机会，我们今年将开始试验，测试这些肌肉保存剂与semaglutide的组合。

According to Yancopoulos, in addition to improved cardiovascular outcomes and blood glucose control, GLP-1-based drugs such as Eli Lilly's (LLY) Zepbound can deliver weight loss, but with up to 40% of weight loss coming from the loss in muscle mass. 'The problem is when patients go off this drug, as the vast majority do within a year, they rapidly regain their weight as fat.

根据Yancopoulos的说法，除了改善心血管结局和血糖控制外，基于GLP-1的药物（如礼来（LLY）Zepbound）可以减轻体重，但高达40%的体重减轻来自肌肉质量的减少。“问题是，当患者停止服用这种药物时，就像绝大多数患者在一年内所做的那样，他们会迅速恢复脂肪的体重。

This is potentially going to lead to a massive public health problem,' he added. Citing preclinical data from a program conducted with Alnylam (NASDAQ:ALNY), Yancopoulos said that silencing the GPR75 gene can completely block body weight gain while leaving muscle mass unchanged. More on Regeneron Regeneron Pharmaceuticals Inc.

他补充说，这可能会导致严重的公共卫生问题。Yancopoulos引用了Alnylam（纳斯达克股票代码：ALNY）进行的一个项目的临床前数据，他说沉默GPR75基因可以完全阻止体重增加，同时保持肌肉质量不变。有关Regeneron Regeneron Pharmaceuticals Inc.的更多信息。

(REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript) Regeneron to post over $1.3B U.S. Eylea sales in Q4 Alvotech rises as biosimilar to Regeneron’s E.

（REGN）第42届摩根大通医疗保健年会-（成绩单）为什么我希望Regeneron在2024年继续为投资者提供服务（升级）Regeneron Pharmaceuticals Inc.（REGN）美国血液学会2023年投资者会议-（成绩单）Regeneron在第四季度美国Eylea销售额超过13亿美元Alvotech随着生物仿制药Regeneron的E而上升。